Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Fused heteroaryl piperidine allosteric modulators: MerckRecent Research Landscape

Off-target binding and poor metabolic stability in M4 receptor ligands lead to clinical failure. These innovations utilize specific heteroaryl piperidine ether architectures to achieve precise allosteric modulation.

What technical problems is Merck addressing in Fused heteroaryl piperidine allosteric modulators?

Receptor desensitization and inactivation

(4)evidences

Impaired cholinergic signaling through alpha-7 nicotinic receptors leads to deficits in memory and sensory gating. Restoring this signaling addresses the underlying pathology of neurodegenerative and psychiatric disorders.

Cholinergic signaling deficiency

(2)evidences

Insufficient activation of muscarinic receptors leads to cognitive and neurological impairment. Restoring receptor sensitivity addresses underlying neurochemical imbalances in psychiatric disorders.